




RealRate

PHARMACEUTICAL 2025

Arrowhead Pharmaceuticals INC
Rank 152 of 225



The relative strengths and weaknesses of Arrowhead Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arrowhead Pharmaceuticals INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Arrowhead Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 74% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	695,471
Cost of Goods Sold	0
Intangible Assets	8,562
Liabilities, Current	103,168
Liabilities, Non-Current	845,571
Other Assets	49,737
Other Compr. Net Income	7,972
Other Expenses	-2,767
Other Liabilities	0
Other Net Income	-11,380
Other Revenues	3,551
Property and Equipment	386,032
Research and Development	505,870
Selling, General and Administrative Expense	98,761

Output Variable	Value in 1000 USD
Assets	1,139,802
Liabilities	948,739
Expenses	601,864
Revenues	3,551
Stockholders Equity	191,063
Net Income	-609,693
Comprehensive Net Income	-605,707
BaseVar	1,356,654
ECR before LimitedLiability	-18%
Economic Capital Ratio	141%